Mystic Pharmaceuticals Receives U.S. Patent for Intranasal Delivery Technology for Pharmaceuticals and Biologics

Published: Feb 07, 2013

AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has been granted U.S. Patent No. 8,377,009, “Intranasal Cartridge Devices” a novel device technology for delivering drugs and biologics into the body via the nasal route. This delivery system is based upon the company’s VersiDoser® and VRx2™ unit dose packaging and delivery platforms. Mystic’s President and CEO, Timothy Sullivan stated that, “The US market for nasal pharmaceuticals is projected to hit $4.25B by 2015 for a broad range of therapeutic drugs. Nasal vaccines will further expand this market opportunity for our technology. Our VersiDoser® and VRx2™ delivery solutions are designed to enhance the patient experience by making these products safer, easier and more convenient to use.” Applications for the company’s intranasal delivery technology include vaccines for infectious diseases such as pandemic or seasonal influenza and therapeutics for pain management, seizure, emesis, depression, hormone therapy and diabetes.

Back to news